Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 31, 2025

Important Notice to Long-Term Shareholders of CarMax, Inc. (NYSE: KMX); Inspire Medical Systems, Inc. (NYSE: INSP); Integer Holdings Corp. (NYSE: ITGR); Lifecore Biomedical, Inc. (NASDAQ: LFCR): Grabar Law Office Investigates Claims on Your Behalf

View original at globenewswire.com
Important Notice to Long-Term Shareholders of CarMax, Inc. (NYSE: KMX); Inspire Medical Systems, Inc. (NYSE: INSP); Integer Holdings Corp. (NYSE: ITGR); Lifecore Biomedical, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Integer overstated its competitive position within the growing EP manufacturing market

    80% confidence
  • Integer's EP devices were a long-term growth driver for the company's C&V segment

    80% confidence
  • Demand for Inspire V was high

    80% confidence
  • Inspire Medical satisfied all regulatory, technical, and commercial conditions for launch of Inspire V

    80% confidence
  • CarMax overstated its growth prospects when earlier growth in fiscal year 2026 was temporary benefit from customers buying cars due to tariff speculation

    80% confidence
  • Integer had strong visibility into customer demand despite experiencing sustained deterioration in sales of two EP devices

    80% confidence
  • Lifecore maintained deficient internal controls over financial reporting

    80% confidence
  • Lifecore's remediation efforts with respect to internal control deficiencies were ineffective

    80% confidence
  • Commercial launch of Inspire V was proceeding successfully

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com